Analysis of individual placements across 43 companies over the past 18 months paints a vivid picture of Japan’s evolving healthcare industry. This comprehensive snapshot illuminates current market demands, strategic shifts, and the enduring appeal of this pivotal Asian market.Rare Diseases…
REGULATORY
CEA Use in Reimbursement Decisions Our Ultimate Goal: MOF Budget Examiner
Japan is to not use its new cost-effectiveness assessment (CEA) scheme for reimbursement decisions - at least for now - but this would give no respite for the industry as budget examiner Iichiro Yoshino says the Ministry of Finance’s (MOF)…
To read the full story
Related Article
- Ensuring Patient Access Was MHLW’s Top Priority for CEA Scheme: Policy Planning Director
April 23, 2019
- With 90% Premium Cut, Japanese CEA Scheme Goes Beyond Its Purpose of Being “Complementary” Tool: FPMAJ Pricing Chief
April 5, 2019
- Ex-Minister Tamura: 3 New Sources of Social Security Funding Needed to Stem Overreliance on Drug Price Cuts
April 3, 2019
- Kyokai Kenpo Director Yoshimori: Japan Should Eventually Use Cost-Effectiveness Assessment to Set Launch Prices
March 29, 2019
- Kenporen Director Kono: Apply CEA to Reimbursement Decisions Once Credible System Established
March 18, 2019
- JMA Exec Matsumoto: CEA Scheme Merely a Supplemental Tool to Drug Pricing System, Continued Discussions Necessary
March 7, 2019
REGULATORY
- Japan Panel to Review Kyowa Kirin’s Libmeldy for Approval on Nov. 9
November 4, 2026
- Public-Private Pharma Talks Expand to Domestic R&D, Manufacturing Investment
November 2, 2026
- Japan’s Healthcare Spending Hits Record 48.8 Trillion Yen in FY2024
November 2, 2026
- PMDA Renews Warning on Off-Label GLP-1 Use amid Adverse Event Reports
November 2, 2026
- PMDA Halts Medical Device Application Platform after Unauthorized Access
October 30, 2026
The approval of Aβ-clearing antibodies like Leqembi (lecanemab) and Kisunla (donanemab) marked a landmark shift toward disease-modifying therapies in Alzheimer’s,…
Members of a key reimbursement policy panel on October 28 raised no objections to expanding drug makers’ access to deliberations…
Japan’s pharmaceutical industry asked the ruling Liberal Democratic Party (LDP) on October 29 to boost the country’s drug supply security…
Eli Lilly’s breast cancer drug Imulrio (imlunestrant) is finally joining Japan’s NHI price list on October 14, nearly 300 days…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…